Eli Lilly (NYSE:LLY) believes its diabetes drug Mounjaro (tirzepatide) will have additional indications for the treatment of obesity as early as the end of the year, according to CFO Anat Ashkenazi.
Speaking at the JP Morgan Medical Conference, Ashkenazi added that the company is building a “clear evidence” to prove that Mounjaro can do more than just help individuals lose weight. This includes benefit data for obstructive sleep apnea, heart failure, and kidney disease.
Ashkenazi suggests that this data can be used to distinguish Mounjaro from Novo Nordisk’s (NVO) Wegovy (semaglutide).
In a phase 3 trial, tirzepatide beat semaglutide about A1C and reduced weight.
Lilly is awaiting action by the US FDA on ongoing submissions for the weight loss indication.
Ashkenazi noted that Mounjaro as a weight loss drug could also benefit if the Obesity Treatment and Reduction Act is passed. The law will cover chronic weight control drugs for Medicare enrollees.
She added that Lilly is expecting the launch of four new molecular entities this year: donanemab (Alzheimer’s disease), lebrikizumab (atopic dermatitis), mirikizumab (ulcerative colitis) and pirtobrutinib (cell lymphoma) coating planing).